Pfizer Drug Hits Goals of Colorectal Cancer Study, Clearing Way to Seek Full FDA Approval

Posted
Pfizer’s Braftovi received accelerated FDA approval in December as a first-line treatment for metastatic colorectal cancer with a particular genetic mutation. The pharma giant now says the drug has hit primary and secondary goals of its Phase 3 clinical trial. The post Pfizer Drug Hits Goals of Colorectal Cancer Study, Clearing Way to Seek Full FDA Approval appeared first on MedCity News.

Continue reading at MedCity News »

BioPharma, Daily, Pharma, biopharma nl, Braftovi, Clinical Trials, colorectal cancer, FDA, Pfizer